{"ticker": {"uuid": "04c1ac47-688d-4400-a389-c61c1fd17b1a", "symbol": "CUV", "name": "Clinuvel Pharmaceuticals Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Is Clinuvel Pharmaceuticals (ASX: CUV) Expanding Beyond SCENESSE\u00ae?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNUGJRQlJFZ1lZS0tvNzctS2tnUjgxbklYTmtjZktKbkxobWt4RlFwTWRKVHFVUmNFUTZXNDFiOTRMS2tmZVIzZW1OS2ZlUTFxRW8zOEQ2dmVLTExucHBkaVRZcjhFb0xSUEpJenBhSmN6Ykk4OEdWSC1PT1pFZ05qZkhxMGpjQWlVOEltWEllR2swa3g1c2wtSVNOTjBxTGVlUVE?oc=5", "source_name": "Kalkine", "published_at": "2026-06-21T12:06:55+00:00", "published_display": "21 Jun 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX 200 Biotech Watch: Can Clinuvel\u2019s Skin Study Deliver?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUVFxcTVKbEV4Z1BJM1ZwZDVfNjQ3bnpFOHo4dmNHd0dseDBGMldvMS1taGF3dXcxT2o2LTdIRXNTS3dKcW5Ld2JuVEZoc0tGejNZZXhiNkEyOUF2eVFqVndrc3VReEpwYmpZUTRhX1dyTnFYRDV2U2c0NGtvR2NaWUZlRUhIandQOHY4b09DNEozRkhZeEJ4bXJ6Nnd5VDhUVDVsag?oc=5", "source_name": "Kalkine Media", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What\u2019s Driving the Recent Drop in Clinuvel Pharmaceuticals (ASX:CUV) Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdWdVY09GTzZnZmcxNGtCX2Z5eF9lZlRkS2VIR0ZtMUU0cnNlZk52VmxrX3J2c1FjNVB1ZEZYeFNSVzNaSzR6SHFxenZiNEJrWl9RTzBZcnQydDI4dWxVeHdhc09aa2dackdmTXJ6OFVpaVoxNVNFYm54S0wwV0V5YUxlZUtlWHQwMmYzbHQ1T0RHZ29qUWpUcWpOUEZTdUZQLVhlOTJOYWFMeWpma2JR?oc=5", "source_name": "Kalkine", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Target Price Cut 3.2% to A$39.20/Share by Jefferies>CUV.AU", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxObE5wQjVwUTF5cWRzX0ttZjYxQXFDZm9CMjBzYXFaVnlURWVEa2RZMGdNZEFoR2ZnWExscUljbl93YVZuc280R3BoS1lJTGZsLUxzUjY3TUxZbjNIcDBfM2dyc3Q1dzN1Q2FQaTU2NmQ0R1BHelBsZURsX0s5dGNIT0UwM05PVjhWdkE?oc=5", "source_name": "Moomoo", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 4DMedical, Clinuvel, Life360, and Silex shares are pushing higher today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPb1hSdl9XdW5PcEFCRlZiUEU0aG1kUVZWc1ZHWWJOMFBvZTVaNjUzZWw4Z3pfZnhfTFVSdXZQUTF6dGtEc0J3dG1NWmgyTkJ4SFRtNU9mWHR4UEo4ZWF5dHFlZGszZDRpdmpfMjVyVXkyTUQ0blJ6Mnk5b3ZWdURqd1lGZllXYmFYNHk3NDNNXzFlaFFNS3RKUzhiRW9XWFMyeWlYclRxNl9CV1Ux?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals (ASX:CUV) - Comprehensive Guide to the Global Specialty Pharmaceutical Leader", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWnoxaTRfd0xYdzVKUldtSEF1MmJNbXRTU09GbnV0c2F3YXF5SzNrb2tqWmhhRlNSd1duWkJiTGIycU1qVE9xUURjMzUyaHJaaHZjUTlBa29GZ1lRNGhOTjcwVlBIWVFLLWEtVUk3eTJldHlCMUlBMHdfNTRsMElTOXZNREg1blN3QzFncHdTYUZRMHA1NEx5MWk0QWUzQzBoWVVYRm0zelhhcW1mMElXUmYxeDZDTFhpN21mMHdNZmdZVDZjcVYzOVN1TlcxdFROMlE?oc=5", "source_name": "Kalkine", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Cash is king in these troubled times, declares defiant Clinuvel", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZ215azBjZTZCWlRVN3E1Tm1xdjI2NHQ3eGV2ZmIzZndHNVVmaEl0R0Ryb29hSmFJM1FXRG1qLTVXUlFWVjdycV9Xdjl5UlN3cEVfcUxTWjF4cnpiOWFieDlqNlMyQ2libXl6akxSdGRhYk80S1AxV2F3a0loRklKRkRHMndETktQeTR3UDgyS0x1bnhvOFRSR0JLRXZfRlJZLUJkdWlVSVJibS0t?oc=5", "source_name": "Stockhead", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals H1 2026 Margin Compression Challenges Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could (ASX:CUV) Be the Next Big ASX Comeback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQeTJoRmVsMy15ckpoSWRhaDhJZUN4c2Q4cVgzcnJpaWpWTUpMY05YSHk1RTJyTndGN1N6MVctM2g4bmlQdVVGOFNTZ1A2dVF2MkVRT0FZX0s3MkxyQUJ3YUVpd0ZiRGU3MFBpXzR4SnhGVWRrRDNySU42MTVna29EOTNBOEM1bnFrbnlWT0hFUEw?oc=5", "source_name": "Kalkine Media", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Clinuvel Pharmaceuticals Ltd (ASX:CUV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE51YmRnN3JHTnNhMGl2NHcwY2RCX3JXVEdlLXFsbzdKSkpLRTQ1UHJSMVlSRndFLTlWRkg3aENzTWRSSWJqemdyOEluM0pJSE5Y?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T15:48:02+00:00", "published_display": "30 Oct 2025 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Strong Earnings and NASDAQ ADR Expansion Plans \u2013 And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNVWE3VjRUVmtGaHlJS1dGU2VEQlhYWXlVR1R3alZpX3p0Y1AtNDd1SVUwcF9OOWVVdEE3MG1lal8yOTJ5RVVqZXRTMEVFcHVUelcwRUVneUtqdWg1ZFNQanV1SWdESHFkRlhCaU9MZ3F2bnQyYm84ZjF1QlJSb2U3UlNLT0hvS01NbWc?oc=5", "source_name": "Market source", "published_at": "2025-09-06T07:00:00+00:00", "published_display": "06 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Clinuvel Pharmaceuticals' (ASX:CUV) Earnings Are Better Than They Seem", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-03T07:00:00+00:00", "published_display": "03 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals (ASX: CUV) Shares Slide as FY25 Costs Rise Despite Profit Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVUNBdlJ2QjZ6NlkyUEdiVGtQbnVjMERua1hObFR1OHZIMS15Q19Tb1Q3UmN2cDk5QUVFVS1CXzdfQ2k5UHVfc0hiSloyOUFmV09NSURwMmlzTUJXNEtwMDdPZk9seFpzaFFYQkV0cG5KNlhwcWVUVm5Fa0x3b3YtSG1SQ2poY1VhSWdvbVlIR2JsOEE4OVlMM20wUWQ2WXlzM1d4ejNMdEtWTnE3OXRYUWY4NlJRNmFsc0JYd0lmNFhWY28?oc=5", "source_name": "Kalkine", "published_at": "2025-08-29T07:00:00+00:00", "published_display": "29 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "It's A Story Of Risk Vs Reward With Clinuvel Pharmaceuticals Limited (ASX:CUV)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals Limited's (ASX:CUV) top owners are individual investors with 60% stake, while 23% is held by institutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPdlFSZ0RCREhFWUNNVUl5QWM2VlJqZW5KcVhOdFRwTzZvb3VWZEhiMmRuSjRwcU91YlF3Z2p4SHRMRkdIOE1fYTZELXIyS1FpU1o3S01OSk5zV2xudVpFcE1tYm9WanlEb2xXV2tLY2NESWtWbGpPeWlfLVNZbmxoVXJVUE9VdXRibllMcUc4Nmc?oc=5", "source_name": "Market source", "published_at": "2025-07-06T07:00:00+00:00", "published_display": "06 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is Clinuvel Pharmaceuticals (ASX: CUV) Expanding Beyond SCENESSE\u00ae?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNUGJRQlJFZ1lZS0tvNzctS2tnUjgxbklYTmtjZktKbkxobWt4RlFwTWRKVHFVUmNFUTZXNDFiOTRMS2tmZVIzZW1OS2ZlUTFxRW8zOEQ2dmVLTExucHBkaVRZcjhFb0xSUEpJenBhSmN6Ykk4OEdWSC1PT1pFZ05qZkhxMGpjQWlVOEltWEllR2swa3g1c2wtSVNOTjBxTGVlUVE?oc=5", "source_name": "Kalkine", "published_at": "2026-06-21T12:06:55+00:00", "published_display": "21 Jun 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX 200 Biotech Watch: Can Clinuvel\u2019s Skin Study Deliver?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUVFxcTVKbEV4Z1BJM1ZwZDVfNjQ3bnpFOHo4dmNHd0dseDBGMldvMS1taGF3dXcxT2o2LTdIRXNTS3dKcW5Ld2JuVEZoc0tGejNZZXhiNkEyOUF2eVFqVndrc3VReEpwYmpZUTRhX1dyTnFYRDV2U2c0NGtvR2NaWUZlRUhIandQOHY4b09DNEozRkhZeEJ4bXJ6Nnd5VDhUVDVsag?oc=5", "source_name": "Kalkine Media", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What\u2019s Driving the Recent Drop in Clinuvel Pharmaceuticals (ASX:CUV) Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdWdVY09GTzZnZmcxNGtCX2Z5eF9lZlRkS2VIR0ZtMUU0cnNlZk52VmxrX3J2c1FjNVB1ZEZYeFNSVzNaSzR6SHFxenZiNEJrWl9RTzBZcnQydDI4dWxVeHdhc09aa2dackdmTXJ6OFVpaVoxNVNFYm54S0wwV0V5YUxlZUtlWHQwMmYzbHQ1T0RHZ29qUWpUcWpOUEZTdUZQLVhlOTJOYWFMeWpma2JR?oc=5", "source_name": "Kalkine", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Target Price Cut 3.2% to A$39.20/Share by Jefferies>CUV.AU", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxObE5wQjVwUTF5cWRzX0ttZjYxQXFDZm9CMjBzYXFaVnlURWVEa2RZMGdNZEFoR2ZnWExscUljbl93YVZuc280R3BoS1lJTGZsLUxzUjY3TUxZbjNIcDBfM2dyc3Q1dzN1Q2FQaTU2NmQ0R1BHelBsZURsX0s5dGNIT0UwM05PVjhWdkE?oc=5", "source_name": "Moomoo", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 4DMedical, Clinuvel, Life360, and Silex shares are pushing higher today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPb1hSdl9XdW5PcEFCRlZiUEU0aG1kUVZWc1ZHWWJOMFBvZTVaNjUzZWw4Z3pfZnhfTFVSdXZQUTF6dGtEc0J3dG1NWmgyTkJ4SFRtNU9mWHR4UEo4ZWF5dHFlZGszZDRpdmpfMjVyVXkyTUQ0blJ6Mnk5b3ZWdURqd1lGZllXYmFYNHk3NDNNXzFlaFFNS3RKUzhiRW9XWFMyeWlYclRxNl9CV1Ux?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals (ASX:CUV) - Comprehensive Guide to the Global Specialty Pharmaceutical Leader", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWnoxaTRfd0xYdzVKUldtSEF1MmJNbXRTU09GbnV0c2F3YXF5SzNrb2tqWmhhRlNSd1duWkJiTGIycU1qVE9xUURjMzUyaHJaaHZjUTlBa29GZ1lRNGhOTjcwVlBIWVFLLWEtVUk3eTJldHlCMUlBMHdfNTRsMElTOXZNREg1blN3QzFncHdTYUZRMHA1NEx5MWk0QWUzQzBoWVVYRm0zelhhcW1mMElXUmYxeDZDTFhpN21mMHdNZmdZVDZjcVYzOVN1TlcxdFROMlE?oc=5", "source_name": "Kalkine", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Cash is king in these troubled times, declares defiant Clinuvel", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZ215azBjZTZCWlRVN3E1Tm1xdjI2NHQ3eGV2ZmIzZndHNVVmaEl0R0Ryb29hSmFJM1FXRG1qLTVXUlFWVjdycV9Xdjl5UlN3cEVfcUxTWjF4cnpiOWFieDlqNlMyQ2libXl6akxSdGRhYk80S1AxV2F3a0loRklKRkRHMndETktQeTR3UDgyS0x1bnhvOFRSR0JLRXZfRlJZLUJkdWlVSVJibS0t?oc=5", "source_name": "Stockhead", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals H1 2026 Margin Compression Challenges Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could (ASX:CUV) Be the Next Big ASX Comeback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQeTJoRmVsMy15ckpoSWRhaDhJZUN4c2Q4cVgzcnJpaWpWTUpMY05YSHk1RTJyTndGN1N6MVctM2g4bmlQdVVGOFNTZ1A2dVF2MkVRT0FZX0s3MkxyQUJ3YUVpd0ZiRGU3MFBpXzR4SnhGVWRrRDNySU42MTVna29EOTNBOEM1bnFrbnlWT0hFUEw?oc=5", "source_name": "Kalkine Media", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Clinuvel Pharmaceuticals Ltd (ASX:CUV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE51YmRnN3JHTnNhMGl2NHcwY2RCX3JXVEdlLXFsbzdKSkpLRTQ1UHJSMVlSRndFLTlWRkg3aENzTWRSSWJqemdyOEluM0pJSE5Y?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T15:48:02+00:00", "published_display": "30 Oct 2025 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Strong Earnings and NASDAQ ADR Expansion Plans \u2013 And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNVWE3VjRUVmtGaHlJS1dGU2VEQlhYWXlVR1R3alZpX3p0Y1AtNDd1SVUwcF9OOWVVdEE3MG1lal8yOTJ5RVVqZXRTMEVFcHVUelcwRUVneUtqdWg1ZFNQanV1SWdESHFkRlhCaU9MZ3F2bnQyYm84ZjF1QlJSb2U3UlNLT0hvS01NbWc?oc=5", "source_name": "Market source", "published_at": "2025-09-06T07:00:00+00:00", "published_display": "06 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Clinuvel Pharmaceuticals' (ASX:CUV) Earnings Are Better Than They Seem", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-03T07:00:00+00:00", "published_display": "03 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals (ASX: CUV) Shares Slide as FY25 Costs Rise Despite Profit Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVUNBdlJ2QjZ6NlkyUEdiVGtQbnVjMERua1hObFR1OHZIMS15Q19Tb1Q3UmN2cDk5QUVFVS1CXzdfQ2k5UHVfc0hiSloyOUFmV09NSURwMmlzTUJXNEtwMDdPZk9seFpzaFFYQkV0cG5KNlhwcWVUVm5Fa0x3b3YtSG1SQ2poY1VhSWdvbVlIR2JsOEE4OVlMM20wUWQ2WXlzM1d4ejNMdEtWTnE3OXRYUWY4NlJRNmFsc0JYd0lmNFhWY28?oc=5", "source_name": "Kalkine", "published_at": "2025-08-29T07:00:00+00:00", "published_display": "29 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "It's A Story Of Risk Vs Reward With Clinuvel Pharmaceuticals Limited (ASX:CUV)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clinuvel Pharmaceuticals Limited's (ASX:CUV) top owners are individual investors with 60% stake, while 23% is held by institutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPdlFSZ0RCREhFWUNNVUl5QWM2VlJqZW5KcVhOdFRwTzZvb3VWZEhiMmRuSjRwcU91YlF3Z2p4SHRMRkdIOE1fYTZELXIyS1FpU1o3S01OSk5zV2xudVpFcE1tYm9WanlEb2xXV2tLY2NESWtWbGpPeWlfLVNZbmxoVXJVUE9VdXRibllMcUc4Nmc?oc=5", "source_name": "Market source", "published_at": "2025-07-06T07:00:00+00:00", "published_display": "06 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 17, "sentiment_summary": {"positive": 4, "negative": 2, "neutral": 11, "score": 54, "total": 17, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 4.4, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 10.3, "latest_week": "2026-06-19", "one_week_move": 15.0, "four_week_move": 13.2, "twelve_week_move": 4.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.063936, "market_dynamics_buy_signal": true, "relative_strength": -6.45066, "fair_value_gap": -22.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 47.086, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+15.0% over one week, +13.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Market Dynamics buy signal", "Value support"], "opportunities": ["Market Dynamics is showing a buy signal in the latest weekly context.", "Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 5}, {"label": "Kalkine", "count": 4}, {"label": "Kalkine Media", "count": 2}, {"label": "Market source", "count": 2}, {"label": "Moomoo", "count": 1}, {"label": "The Motley Fool Australia", "count": 1}, {"label": "Stockhead", "count": 1}, {"label": "smallcaps.com.au", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 17}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 8}, {"label": "Earnings", "count": 5}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "17", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+15.0% over one week, +13.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Is Clinuvel Pharmaceuticals (ASX: CUV) Expanding Beyond SCENESSE\u00ae?"}], "updated_at": "2026-06-22T20:27:12.134066+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}